Mainz Biomed to Participate in Digestive Disease Week 2023
May 01, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, May 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
April 27, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
April 26, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending
April 11, 2023 09:00 ET
|
Mindera Health
San Diego, CA, April 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, has initiated a coverage with evidence project...
Mainz Biomed Provides Full Year 2022 Financial Results
April 10, 2023 03:01 ET
|
Mainz BioMed NV
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V....
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
April 04, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
March 29, 2023 03:01 ET
|
Mainz BioMed NV
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced adenoma...
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
March 21, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Global Clinical Diagnostics Market Size & Analysis
March 20, 2023 12:11 ET
|
Global Market Estimates
Brooklyn, New York, March 20, 2023 (GLOBE NEWSWIRE) -- According to a recently revamped/updated market research report published by Global Market Estimates, the Global Clinical Diagnostics Market is...
IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution
March 20, 2023 06:30 ET
|
Brain Scientific Inc.
BRENTWOOD, Tenn. and LAKEWOOD RANCH, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IMAC Holdings, Inc. (“IMAC”) (Nasdaq: BACK), a regenerative rehabilitation company focused on...